Rifaximin ameliorates intestinal inflammation in cirrhotic patients with hepatic encephalopathy

Yasuyuki Tamai; Motoh Iwasa; Akiko Eguchi; Ryuta Shigefuku; Yoshihiro Kamada; Eiji Miyoshi; Yoshiyuki Takei

doi:10.1002/jgh3.12596

Rifaximin ameliorates intestinal inflammation in cirrhotic patients with hepatic encephalopathy

JGH Open. 2021 Jun 23;5(7):827-830. doi: 10.1002/jgh3.12596. eCollection 2021 Jul.

Authors

Yasuyuki Tamai¹, Motoh Iwasa¹, Akiko Eguchi¹, Ryuta Shigefuku¹, Yoshihiro Kamada², Eiji Miyoshi², Yoshiyuki Takei¹

Affiliations

¹ Department of Gastroenterology and Hepatology Mie University Graduate School of Medicine Tsu Japan.
² Department of Molecular Biochemistry and Clinical Investigation Osaka University Graduate School of Medicine Osaka Japan.

Abstract

Rifaximin (RFX) treatment can attenuate not only hyperammonemia but also Enterococcus faecalis translocation and 10-7G values, suggesting that RFX treatment may improve intestinal inflammation and result in better overall survival.

Keywords: hepatic encephalopathy; intestinal inflammation; liver cirrhosis; rifaximin.